Add BrightSurf on Google Email

Centro Nacional de Investigaciones Oncológicas (CNIO)


A patient with kidney cancer overcomes several metastases against all expectations. CNIO researchers discover why and pave the way for similar cases

A patient with kidney cancer overcame several metastases with temsirolimus, leading researchers to identify key mutations that make this treatment effective. The study found that patients with USP9X mutations have altered autophagy and respond better to temsirolimus.

SourceCentro Nacional de Investigaciones Oncológicas (CNIO)·JournalInternational Journal of Cancer·TypeExperimental study·DateJun 14, 2023

Specifically designed diets demonstrate a “powerful ability” to prevent tumorigenesis, delay tumor growth and improve existing cancer treatments, CNIO researchers say in a review paper

CNIO researchers review the anticancer effects of various diets, including caloric restriction, ketogenic diet, and intermittent fasting. They argue that precision nutrition can be used to treat specific cancers based on tumor metabolism and patient characteristics.

SourceCentro Nacional de Investigaciones Oncológicas (CNIO)·JournalTrends in Molecular Medicine·TypeLiterature review·DateMay 30, 2023

Targeting telomeres might be an effective therapeutic strategy against lung cancer, according to a CNIO study

Researchers have studied targeting telomeres as a potential therapeutic strategy for non-small cell lung cancer. Telomere dysfunction and telomerase deficiency slowed tumor progression, increasing vulnerability to DNA damage and immune system response.

SourceCentro Nacional de Investigaciones Oncológicas (CNIO)·JournalCell Death and Differentiation·TypeExperimental study·DateMay 25, 2023

The search for the origin of a rare tumor points to a poorly studied mechanism as a new would-be hot topic in cancer research: ‘succinylation’

Scientists at CNIO identify succinylation as a poorly studied mechanism in cancer research; mutated DLST protein prevents succinylation, leading to pseudohypoxia and tumor growth. Succinylation is crucial for protein function and may be linked to various diseases.

SourceCentro Nacional de Investigaciones Oncológicas (CNIO)·JournalCancer Communications·TypeExperimental study·DateMay 9, 2023

CNIO researchers help to understand the functioning of the protein that makes DNA loops in the human genome

Researchers at the CNIO have elucidated a key point about how cohesin attaches to DNA and forms loops. The study suggests that NIPBL is not necessary for cohesin to bind to DNA, but only for it to move and form DNA loops. This finding may be important in understanding Cornelia de Lange syndrome.

SourceCentro Nacional de Investigaciones Oncológicas (CNIO)·JournalNature Communications·TypeExperimental study·DateMar 29, 2023

Scientists identify the mechanisms leading to resistance to lung cancer treatment with Sotorasib, the first KRAS inhibitor

Researchers studied how tumors adapt to Sotorasib and found that gene amplification and transcriptional programs lead to resistance. This knowledge can help develop targeted treatments for patients with KRAS mutations, potentially increasing survival rates.

SourceCentro Nacional de Investigaciones Oncológicas (CNIO)·JournalJournal of Clinical Investigation·TypeExperimental study·DateMar 17, 2023

CNIO researchers propose biomarkers to select breast cancer patients who could benefit from denosumab treatment

Researchers have identified a biomarker that can select breast cancer patients who may benefit from denosumab treatment. The study found that tumors with high RANK protein expression are associated with poor prognosis and response to chemotherapy, suggesting that denosumab may be effective in hormone-receptor negative tumors.

SourceCentro Nacional de Investigaciones Oncológicas (CNIO)·JournalEMBO Molecular Medicine·TypeObservational study·DateMar 7, 2023

The largest genomic study of rare cancer metastathic pheochromocytoma identifies patients at highest risk of metastasis and those who would respond to immunotherapy

Researchers have identified markers associated with an increased risk of metastasis in patients with metastatic pheochromocytoma, allowing for personalized clinical management. The study also identifies patients who could benefit from immunotherapy treatments, paving the way for potential new therapies.

SourceCentro Nacional de Investigaciones Oncológicas (CNIO)·JournalNature Communications·TypeObservational study·DateFeb 28, 2023

Molecular basis of resistance to one of the main treatments for multiple myeloma identified

Researchers at CNIO have identified epigenetic changes, specifically DNA methylation, as a key mechanism behind resistance to proteasome inhibitor drugs in multiple myeloma. This finding suggests that methylation levels in the PSMD5 gene can predict treatment response and potentially reverse resistance.

SourceCentro Nacional de Investigaciones Oncológicas (CNIO)·JournalClinical Cancer Research·TypeExperimental study·DateNov 7, 2022

The exceptional case of a person who has survived 12 tumors opens up new avenues for early diagnosis and immunotherapy in cancer, say CNIO researchers

Researchers discover exceptional individual with 12 tumors, shedding light on early detection methods and immune system response. Single-cell analysis technology shows promise in identifying cells with tumor potential before symptoms appear.

SourceCentro Nacional de Investigaciones Oncológicas (CNIO)·JournalScience Advances·TypeCase study·DateNov 2, 2022

Treatment of pulmonary fibrosis should focus on the telomeres of the cells that regenerate the lungs, according to a new study by CNIO researchers

Researchers at CNIO have identified alveolar type II pneumocytes as the primary cell type responsible for developing pulmonary fibrosis. The study reveals that targeting these cells through telomere-based therapy may lead to a breakthrough in treating this debilitating disease.

SourceCentro Nacional de Investigaciones Oncológicas (CNIO)·JournalNature Communications·TypeExperimental study·DateOct 6, 2022

Discovered key mechanisms to improve intestinal regeneration and alleviate the side effects of radiotherapy

Researchers have discovered a cellular and molecular mechanism essential for intestinal epithelial regeneration. Progenitor cells modulate the production of mitogenic factors, controlling intestinal stem cell proliferation and tissue regeneration. This finding breaks new ground in research into counteracting radiotherapy side effects.

SourceCentro Nacional de Investigaciones Oncológicas (CNIO)·JournalJournal of Experimental Medicine·TypeExperimental study·DateSep 14, 2022

A ‘weak spot’ discovered that potentially makes multi-drug resistant tumors vulnerable

A team of researchers has discovered a link between the FBXW7 gene and multidrug resistance in tumors, suggesting that targeting this vulnerability could lead to new treatment options. The study found that FBXW7-deficient cells are more susceptible to certain types of drugs that activate the integrated stress response.

SourceCentro Nacional de Investigaciones Oncológicas (CNIO)·JournalEMBO Molecular Medicine·DateJul 22, 2022

CNIO researchers design a drug screening platform compatible with patient biopsies to fight metastasis

Researchers have designed METPlatform, a drug screening platform compatible with patient biopsies, to investigate patients' own tumour tissue. The platform has identified new therapeutic targets and biomarkers for aggressive brain metastases, suggesting HSP90 inhibitors as potential treatments.

SourceCentro Nacional de Investigaciones Oncológicas (CNIO)·JournalEMBO Molecular Medicine·DateFeb 17, 2022

CNIO researchers identify drugs potentially capable of reducing the mortality of COVID-19

Researchers have identified potential anti-inflammatory compounds to combat the cytokine storm, a key factor in severe COVID-19 cases. The study found that glucocorticoids and MEK protein inhibitors may be effective in reducing mortality, while female hormones could also play a role.

SourceCentro Nacional de Investigaciones Oncológicas (CNIO)·JournalScientific Reports·TypeComputational simulation/modeling·DateJan 31, 2022

CNIO researchers shed light on the maturation of spliceosome, a cellular process involved in certain types of cancer

Researchers have shed light on the role of RUVBL1 and RUVBL2 proteins in the assembly and maturation of the spliceosome, a complex involved in cell splicing and alternative splicing. The study provides insights into the mechanisms responsible for the maturation of the splicing machinery.

SourceCentro Nacional de Investigaciones Oncológicas (CNIO)·JournalNucleic Acids Research·TypeExperimental study·DateDec 29, 2021

Scientists from CNIO and Massachusetts General Hospital develop tools to visualize DNA repair as never before

Scientists from CNIO and Massachusetts General Hospital have developed new approaches to visualize DNA repair by analyzing hundreds of proteins at once. They discovered nine new proteins involved in DNA repair and identified key players in the process, which could lead to improved cancer treatments.

SourceCentro Nacional de Investigaciones Oncológicas (CNIO)·JournalCell Reports·TypeExperimental study·DateDec 28, 2021

CNIO researchers discover a new mechanism involved in early melanoma metastasis

CNIO researchers have identified a new biomarker for early melanoma metastasis, proposing the use of NGFR to predict disease prognosis and define risk groups. Blocking NGFR drastically reduces metastasis in mice, paving the way for a potential first treatment to tackle metastasis in its earliest stages.

SourceCentro Nacional de Investigaciones Oncológicas (CNIO)·JournalNature Cancer·TypeExperimental study·DateNov 25, 2021

Researchers at CNIO and 12 de Octubre Hospital prove efficacy of new immunotherapy for multiple myeloma

Researchers at CNIO and 12 de Octubre Hospital have developed a new cancer treatment called CAR-NK-cell immunotherapy, which uses natural killer cells to target cancerous cells. The treatment has shown promising results in mice with multiple myeloma, with 25% of treated mice remaining disease-free.

SourceCentro Nacional de Investigaciones Oncológicas (CNIO)·JournalBlood Cancer Journal·TypeExperimental study·DateOct 6, 2021

CNIO researchers clarify the role of the two isoforms of KRAS, the most common oncogene in humans

A study by CNIO researchers found that both isoforms of the KRAS oncogene are oncogenic and must be targeted for therapies to be effective. The research suggests that KRAS4A mutant is even more active than previously thought, inducing lung cancer and metastasis in 20% of individuals.

SourceCentro Nacional de Investigaciones Oncológicas (CNIO)·JournalProceedings of the National Academy of Sciences·DateJul 19, 2021

CNIO researchers find molecular switch that allows organisms to adapt to fasting conditions

Researchers at CNIO have identified RagA as a molecular switch that allows cells to adapt to low nutrient levels, enabling an 'energy-saving mode' similar to what occurs in yeasts. This discovery has significant implications for understanding metabolic regulation and potential strategies to fight obesity and related diseases.

Open door to treatment of renal fibrosis by showing that it is caused by telomere shortening

Renal fibrosis, a leading cause of kidney failure, has been linked to telomere shortening. Researchers found that short telomeres exacerbate epithelial-to-mesenchymal transition, promoting pathological scarring of kidney tissue. They propose treating renal fibrosis by lengthening telomeres and restoring normal gene expression.

The immunomodulatory activity of a drug would improve the efficacy of immunotherapy in breast cancer

A new study suggests that targeting the RANK signaling pathway can enhance antitumor immune responses, making breast cancer more responsive to immunotherapy. The findings come from a clinical trial and preclinical research, demonstrating the potential of this approach to convert 'cold' tumors into 'warm' ones.